Stoke Therapeutics (STOK) Depreciation & Amortization (CF) (2018 - 2026)
Stoke Therapeutics (STOK) recorded quarterly Depreciation & Amortization (CF) of $439000.0 in Q1 2026, up 8.4% quarter-over-quarter from $405000.0 in Q4 2025, and down 7.97% on a YoY basis from $477000.0 in Q1 2025.
Stoke Therapeutics (STOK) Depreciation & Amortization (CF) (2018 - 2026) Analysis & Trends
Stoke Therapeutics' Depreciation & Amortization (CF) history runs 9 years deep, the most recent figure standing at $439000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 7.97% year-over-year to $439000.0; the TTM figure through Mar 2026 stood at $1.7 million (down 18.07% YoY), while the FY2025 annual figure was $1.8 million, down 19.55% from the prior year.
- Depreciation & Amortization (CF) was $439000.0 for Q1 2026 at Stoke Therapeutics, up from $405000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $637000.0 in Q3 2023 to a low of $247000.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $495529.4 across 5 years, with a median of $540000.0 in 2024.
- The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) soared 141.7% in 2023, then slipped 26.23% in 2025.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $609000.0 in 2022, then climbed by 2.46% to $624000.0 in 2023, then retreated by 12.02% to $549000.0 in 2024, then retreated by 26.23% to $405000.0 in 2025, then grew by 8.4% to $439000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $439000.0 (Q1 2026), $405000.0 (Q4 2025), and $442000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.95 Bn | - | 439,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 439,000.00 |
| Mar 31, 2026 | 439,000.00 |
| Dec 31, 2025 | 405,000.00 |
| Dec 31, 2025 | 405,000.00 |
| Sep 30, 2025 | 442,000.00 |
| Sep 30, 2025 | 442,000.00 |
| Jun 30, 2025 | 446,000.00 |
| Jun 30, 2025 | 446,000.00 |
| Mar 31, 2025 | 477,000.00 |
| Mar 31, 2025 | 477,000.00 |
| Dec 31, 2024 | 549,000.00 |
| Dec 31, 2024 | 549,000.00 |
| Sep 30, 2024 | 540,000.00 |
| Sep 30, 2024 | 540,000.00 |
| Jun 30, 2024 | 548,000.00 |
| Jun 30, 2024 | 548,000.00 |
| Mar 31, 2024 | 563,000.00 |
| Mar 31, 2024 | 563,000.00 |
| Dec 31, 2023 | 624,000.00 |
| Dec 31, 2023 | 624,000.00 |